Poster Abstracts
Grand Hall CD (Manchester Grand Hyatt)
Feasibility of Hematopoietic Stem Cell Transplantation for T-Prolymphocytic Leukemia. Experience of a Large Referral Center
Moussab Damlaj, MD, Mayo Clinic;
Shahrukh Hashmi, MD, MPH, Mayo Clinic Rochester;
Timothy Call, MD, Mayo Clinic;
Thomas E Witzig, MD, Mayo Clinic;
Grzegorz S Nowakowski, MD, Mayo Clinic;
Tait Shanafelt, MD, Mayo Clinic;
Wei Ding, MD, Mayo Clinic;
Jennifer Oliveira, Mayo Clinic;
Rhett Ketterling, Mayo Clinic;
Mark R. Litzow, MD, Mayo Clinic Rochester;
William Hogan, MBBCh, Mayo Clinic;
Mrinal Patnaik, MBBS, Mayo Clinic
Myeloablative Haploidentical Stem Cell Transplantation (MAC-HAPLO) with Post-Transplant Cyclophosphamide (PT-CY) As Gvhd Prophylaxis in High Risk Leukemias/Myelosdisplastic Syndromes (MDS)
Jorge Gayoso, HGU Gregorio Marañón;
Pascual Balsalobre, HGU Gregorio Marañón;
Mi Kwon, HGU Gregorio Marañón;
Antonia Sampol, Hospital Son Espasses;
Pau Montesinos, Hospital U. La Fe;
David Serrano, HGU Gregorio Marañón;
Pilar Herrera, Hospital Ramón y Cajal;
Maria Jesús Pascual, Hospital Carlos Haya;
Arancha Bermúdez, Hospital Marqués de Valdecilla;
Cristina Castilla-Llorente, Hospital Morales Messeguer;
Leyre Bento, Hospital Son Espasses;
Diana Champ, HGU Gregorio Marañón;
Ana Pérez-Corral, HGU Gregorio Marañón;
Elena Buces, HGU Gregorio Marañón;
José Luis Diez-Martin, HGU Gregorio Marañón
Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) Following Blinatumomab-Induced Remission in Pediatric Patients with Relapsed/Refractory (r/r) B-Precursor Acute Lymphoblastic Leukemia (ALL): Preliminary Results from a Phase I/II Stud
Rupert Handgretinger, University of Tübingen;
Lia Gore, Children’s Hospital Colorado;
Gerhard Zugmaier, Amgen Research (Munich) GmbH;
Franco Locatelli, University of Pavia;
Christian M. Zwaan, Sophia Children’s Hospital;
Deepa Bhojwani, St Jude Children's Research Hospital;
Peter Bader, University of Frankfurt;
Maureen M. O'Brien, Cincinnati Children's Hospital Medical Center;
Tanya M. Trippett, Memorial Sloan-Kettering Cancer Center;
Benoît Brethon, Hôpital Robert Debré;
Carmelo Rizzari, University of Milano-Bicocca;
Paul Gerhardt Schlegel, University Children’s Hospital Würzburg;
Gérard Michel, Hôpital de la Timone;
Phillip Barnette, Primary Children's Medical Center;
Chiara Messina, Università degli Studi di Padova;
Kuolung Hu, Amgen Inc.;
Noemi Mergen, Amgen Research (Munich) GmbH;
Anja Fischer, Amgen Research (Munich) GmbH;
James Whitlock, Hospital for Sick Children;
Arend von Stackelberg, Charité Campus Virchow
Race Influences the Response to Conventional Induction Chemotherapy in Asian Patients with Acute Myeloid Leukemia
Ying Shi Ho, BSc(Pharm)(Hons), Singapore General Hospital;
Hong Yen Ng, BSc(Pharm)(Hons), Singapore General Hospital;
Vivien WP Tham, BSc(Pharm)(Hons), Singapore General Hospital;
Hung Chew Wong, National University of Singapore, National University Health System;
William Y K Hwang, FRCP, FAMS, MMed, MRCP, MBBS, Singapore General Hospital;
Gee Chuan Wong, MBBS, MMed, (Int, Med), FRCP, FAMS, Singapore General Hospital
Is Lymphoid Leukemia Less Susceptible to Busulfan Than Myeloid Leukemia? Comparison of Cytotoxicities of Busulfan, Melphalan, Fludarabine, Clofarabine, Cytosine Arabinoside, and Etoposide in Human Myeloid and Lymphoid Leukemia Cell Lines
Masaru Kamishohara, DVM, PhD, Otsuka Pharmaceutical Co., Ltd.;
Hirofumi Komatsubara, PhD, Hamri Co., Ltd.;
Hayato Kakinuma, Hamri Co., Ltd.;
Ryo Tanaka, Hamri Co., Ltd.;
Yuki Nakamura, Otsuka Pharmaceutical Co., Ltd.;
Hiroyuki Kobayashi, MD, PhD, Otsuka Pharmaceutical Co., Ltd.
Relapse after Allogeneic Hematopoietic Stem Cell Transplantation (HCT) in AML/MDS: Monocyte Chemo-Attractant Protein-1 (MCP-1) Levels Post HCT and Prediction of Relapse in Patients with Hematological Remission and Full Chimerism at Day 30
Yasser Khaled, MD, Florida Hospital Cancer Institute;
Rushang D Patel, MD, PhD, Florida Hospital Cancer Institute;
Sharam Mori, MD, Florida Hospital Cancer Institute;
Wesam Ahmed, MD, Florida Hospital Cancer Institute;
Yasmin Abaza, MD, Florida Hospital Cancer Institute;
Melhem Solh, MD, Florida Hospital Cancer Institute
Targeting BCL-2 and BCR-Abl Activity in Ph+ALL
Jessica T Leonard, MD, Oregon Health & Science University;
Elie Traer, MD, PhD, Oregon Health & Science University;
Brandon Hayes-Lattin, MD, Oregon Heath & Science University;
Jeffrey Tyner, PhD, Oregon Health & Science University;
Brian Druker, MD, Oregon Health and Science University;
Bill H Chang, MD, PhD, Oregon Health & Science Univ CDRCP DCH
Preclinical Development of Cord Blood-Derived Dendritic Cell-Based Immunotherapies after Hematopoietic Cell Transplantation in Children with AML
Colin de Haar, PhD, UMC Utrecht;
Maud Plantinga, PhD, UMC Utrecht;
Nina Blokland, UMC Utrecht;
Ester Dunnebach, UMC Utrecht;
Marianne Boes, PhD, UMC Utrecht;
Jaap-Jan Boelens, MD, PhD, University Medical Center Utrecht;
Stefan Nierkens, PhD, UMC Utrecht
Early Response to Initial Induction Chemotherapy in Acute Myeloid Leukemia (AML) and Outcomes after Allogeneic Hematopoietic Cell Transplant (HCT)
Masumi Ueda, MD, University Hospitals Seidman Cancer Center and Case Western Reserve University;
Pingfu Fu, PhD, Case Western Reserve University;
Merle Kolk, University Hospitals Seidman Cancer Center and Case Western Reserve University;
Richard Creger, PharmD, University Hospitals Seidman Cancer Center and Case Western Reserve University;
Paolo Caimi, MD, University Hospitals Seidman Cancer Center and Case Western Reserve University;
Brenda Cooper, MD, University Hospitals Seidman Cancer Center and Case Western Reserve University;
Hillard M. Lazarus, MD, University Hospitals Seidman Cancer Center and Case Western Reserve University;
Marcos J. G. de Lima, MD, University Hospitals Seidman Cancer Center and Case Western Reserve University
Comparison of the Cytotoxicity of Cladribine and Clofarabine When Combined with Fludarabine and Busulfan in AML Cells: Enhancement of Cytotoxicity with Epigenetic Modulators
Ben C. Valdez, PhD, UT M.D. Anderson Cancer Center;
David Murray, PhD, Cross Cancer Institute;
Yang Li, MS, UT MD Anderson Cancer Center;
Kendrick Katigbak, UT MD Anderson Cancer Center;
Jie Ji, MD, UT MD Anderson Cancer Center;
Yan Liu, UT MD Anderson Cancer Center;
Uday R. Popat, MD, UT MD Anderson Cancer Center;
Richard E. Champlin, MD, The University of Texas MD Anderson Cancer Center;
Borje S. Andersson, MD, PhD, The University of Texas MD Anderson Cancer Center
![[Visit Client Website]](images/banner.gif)